previous
develop
replicationcompet
b
replicationdefici
c
chemic
inactiv
rabi
viru
rabv
vaccin
express
ebolaviru
ebov
glycoprotein
gp
induc
humor
immun
viru
confer
protect
lethal
rabv
mouseadapt
ebov
challeng
mice
expand
investig
immunogen
properti
bival
vaccin
mice
live
kill
vaccin
induc
primari
ebov
gpspecif
tcell
robust
recal
respons
measur
elispot
assay
addit
cellular
immun
effect
filoviru
vaccin
like
requir
multival
humor
immun
respons
multipl
viru
speci
proofofprincipl
experi
demonstr
inactiv
rvgp
could
formul
anoth
inactiv
rabv
vaccin
express
nontox
fragment
botulinum
neurotoxin
heavi
chain
without
reduct
immun
compon
final
demonstr
humor
immun
gp
could
induc
immun
mice
inactiv
rvgp
presenc
preexist
immun
rabv
abil
novel
vaccin
induc
strong
humor
cellular
immun
indic
evalu
addit
anim
model
infect
sever
viral
speci
ebolaviru
genu
marburgviru
genu
famili
filovirida
caus
sever
often
fatal
viral
hemorrhag
fever
human
nonhuman
primat
search
multival
filoviru
vaccin
confer
protect
ebola
viru
ebov
marburg
viru
speci
public
health
concern
continu
candid
approach
licensur
high
case
fatal
rate
public
health
threat
africa
biodefens
concern
associ
virus
drive
vaccin
develop
sever
vaccin
strategi
develop
past
decad
confer
protect
anim
model
issu
safeti
preexist
vector
immun
manufactur
lack
commerci
interest
slow
progress
recent
studi
literatur
review
attempt
determin
correl
protect
filoviru
vaccin
defin
abil
humor
cellular
immun
amelior
diseas
surprisingli
appear
humor
cellular
arm
immun
respons
contribut
protect
recent
develop
replicationcompet
b
replicationdefici
c
chemic
inactiv
rabi
viru
rabv
vaccin
express
ebov
zair
glycoprotein
gp
recombin
rabv
vaccin
vector
rva
deriv
sad
strain
use
wildlif
vaccin
europ
previous
use
safe
efficaci
platform
gener
vaccin
candid
sever
pathogen
two
live
vaccin
candid
rvgp
delet
remov
entir
rabv
glycoprotein
g
gene
found
avirul
upon
peripher
administr
mice
base
effici
incorpor
gp
virion
inactiv
vaccin
inacrvgp
also
produc
treatment
betapropiolacton
standard
method
util
current
human
rabv
vaccin
bival
vaccin
candid
induc
strong
humor
immun
rabv
g
ebov
gp
confer
protect
lethal
rabv
mouseadapt
ebov
challeng
mice
primari
focu
develop
inactiv
vaccin
use
human
base
potenti
superior
safeti
histori
success
exist
rabv
vaccin
wide
use
human
also
pursu
live
attenu
vaccin
candid
use
nonhuman
primat
popul
africa
risk
lethal
ebov
infect
expand
investig
immun
respons
rabv
vaccin
candid
express
ebov
gp
three
critic
element
effect
vaccin
platform
filovirus
assess
abil
induc
ebovspecif
tcell
immun
b
coformul
vaccin
candid
induc
multival
antibodi
respons
c
induct
gpspecif
immun
presenc
preexist
vector
immun
rabv
vaccin
recoveri
propag
vaccin
candid
use
studi
describ
previous
viru
serv
parent
rabi
vaccin
vector
rva
figur
rvgp
express
ebov
mayinga
gp
ectodomain
transmembran
domain
fuse
rabv
g
cytoplasm
domain
inactiv
rvgp
inacrvgp
gener
treatment
sucros
purifi
viru
stock
dilut
betapropiolacton
bpl
overnight
follow
min
express
intact
ebov
mayinga
gp
contain
delet
rabv
g
gene
requir
propag
complementari
cell
express
rabv
g
bpl
inactiv
express
chimer
protein
compos
heavi
chain
carboxytermin
half
botulinum
neurotoxin
fuse
amino
acid
rabv
g
ectodomain
ed
transmembran
domain
tm
cytoplasm
domain
cd
recombin
vaccinia
viru
express
ebov
mayinga
gp
construct
use
publish
method
mous
experi
approv
niaid
divis
intramur
research
anim
care
use
committe
inject
ml
live
inactiv
viru
administ
via
intramuscular
im
rout
hind
leg
live
vaccin
deliv
ffu
kill
vaccin
equival
approxim
ffu
deliv
day
day
group
balbc
mice
jackson
laboratori
immun
either
vehicl
rva
parent
viru
rvgp
inacrvgp
inacrvgp
addit
dose
day
analysi
primari
cell
respons
four
mice
per
group
sacrif
day
postimmun
splenocyt
assay
individu
mous
elispot
figur
analysi
memori
recal
respons
six
mice
per
group
challeng
day
immun
intraperiton
ip
inocul
pfu
vaccinia
viru
express
ebov
gp
spleen
remov
five
day
later
assay
individu
mous
elispot
figur
analysi
humor
immun
group
five
balbc
mice
immun
day
day
singl
inactiv
vaccin
coformul
inacrvgp
viru
analysi
abil
induc
ebov
gpspecif
humor
immun
presenc
rabv
immun
group
five
balbc
mice
immun
follow
immun
inacrvgp
day
later
experi
serum
collect
four
six
week
postimmun
individu
analysi
although
volum
restraint
requir
sera
pool
group
singl
cell
suspens
splenocyt
prepar
previous
describ
mous
elispot
kit
r
system
use
assay
plate
block
complet
medium
iscov
mdm
supplement
fb
betamercaptoethanol
hour
room
temperatur
block
media
remov
antigen
dilut
fresh
complet
media
ad
respect
well
ebov
gp
peptid
pool
influenza
np
tyqrtralv
ebov
gp
peptid
pool
consist
overlap
amino
acid
acquir
jpt
peptid
technolog
unstimul
well
contain
complet
media
one
hundr
thousand
cell
ad
well
plate
incub
hour
humidifi
incub
co
plate
wash
process
accord
manufactur
instruct
spot
enumer
use
immunospot
reader
immunospot
softwar
cellular
technolog
ltd
humor
immun
assess
elisa
rabv
g
ebov
gp
botulinum
neurotoxin
briefli
maxisorp
well
elisa
plate
nunc
coat
respect
antigen
overnight
previous
describ
coat
buffer
remov
plate
wash
pb
tween
sera
dilut
threeor
fourfold
increment
plate
incub
overnight
wash
repeat
secondari
hrpconjug
antibodi
ad
respect
rt
wash
repeat
substrat
ad
well
plate
incub
min
room
temp
stop
solut
ad
determin
use
plate
reader
data
analyz
prism
softwar
graphpad
elispot
result
group
compar
via
oneway
anova
dunnett
multipl
comparison
test
use
rva
control
unpair
twotail
ttest
use
elisa
data
analysi
welch
correct
varianc
unequ
previous
demonstr
live
inactiv
rabv
vaccin
express
gp
potent
induc
humor
immun
rabv
g
zebov
gp
howev
evid
previou
vaccin
strategi
tcell
mediat
immun
may
import
induct
protect
immun
filovirus
therefor
attempt
determin
live
kill
vaccin
candid
induc
primari
memori
gpspecif
tcell
use
murin
elispot
assay
gp
peptid
pool
irrelev
influenza
peptid
stimul
primari
respons
day
postimmun
figur
live
inactiv
vaccin
candid
found
induc
gpspecif
splenocyt
level
observ
vehicl
rva
control
group
compar
rva
immun
live
rvgp
result
significantli
higher
level
splenocyt
p
mean
spot
per
million
cell
spmc
one
two
dose
inacrvgp
result
mean
number
spmc
critic
measur
cellular
immun
respons
abil
recal
function
activ
cell
upon
viral
challeng
therefor
analyz
memori
recal
tcell
respons
immun
mice
challeng
ip
pfu
vaccinia
viru
express
ebov
gp
serv
surrog
challeng
viru
four
week
postimmun
immun
rvgp
inacrvgp
induc
recal
respons
detect
higher
level
gpspecif
splenocyt
compar
vehicl
rva
control
group
observ
primari
respons
rvgp
induc
significantli
higher
level
memori
cell
rva
mean
spmc
p
replicationdefici
viru
inactiv
vaccin
inacrvgp
also
induc
elev
cell
respons
mean
spmc
respect
addit
two
dose
inacrvgp
induc
recal
cell
respons
level
compar
live
vaccin
significantli
higher
rva
respons
mean
spmc
p
previous
demonstr
rabv
vaccin
express
gp
effect
induc
bival
rabv
gspecif
ebov
gpspecif
antibodi
respons
howev
effect
filoviru
vaccin
like
need
confer
immun
sever
viral
speci
next
sought
determin
coadministr
addit
rabv
vector
vaccin
would
result
induct
multival
antibodi
respons
three
vaccin
antigen
proof
principl
experi
util
previous
report
inactiv
rabv
vector
vaccin
express
fragment
botulinum
neurotoxin
term
coadminist
inacrvgp
determin
multival
antibodi
respons
rabv
g
botulinum
ebov
gp
could
induc
group
five
mice
immun
im
day
twice
day
inacrvgp
combin
administr
viru
indic
figur
vaccin
approach
induc
strong
antibodi
respons
rabv
g
expect
sinc
rabv
g
present
immunogen
either
singl
dose
two
dose
induc
botulinum
antibodi
interestingli
combin
administr
inacrvgp
result
slightli
stronger
respons
figur
final
analysi
gpspecif
antibodi
respons
indic
singl
boost
immun
inacrvgp
induc
strong
immun
expect
figur
importantli
coadministr
inacrvgp
induc
antibodi
level
nearli
ident
inacrvgp
immun
result
indic
potent
multival
respons
induc
inactiv
vaccin
platform
coimmun
three
antigen
rabv
g
zebov
gp
result
decreas
antibodi
respons
individu
immunogen
possibl
member
target
popul
ebola
vaccin
lab
worker
first
respond
may
previous
vaccin
current
approv
rabv
vaccin
thu
preexist
immun
rabv
preexist
immun
might
interfer
induct
ebov
gpspecif
antibodi
upon
immun
inacrvgp
therefor
sought
determin
mous
model
prior
vaccin
rabv
vaccin
would
inhibit
induct
gpspecif
antibodi
sever
vaccin
strategi
demonstr
confer
protect
ebola
hemorrhag
fever
macaqu
includ
dna
vaccin
viruslik
particl
recombin
virus
express
gp
includ
adenoviru
vesicular
stomat
viru
paramyxovirus
expect
vaccin
candid
compris
advantag
disadvantag
regard
safeti
concern
preexist
vector
immun
manufactur
dosageschedul
issu
abil
induc
variou
compon
immun
respons
experi
describ
design
build
upon
initi
find
live
inactiv
rabv
vaccin
express
gp
induc
strong
humor
immun
confer
protect
rabv
ebov
mice
studi
sought
support
thorough
futur
investig
immun
protect
efficaci
macaqu
believ
serv
best
anim
model
studi
filoviru
hemorrhag
fever
base
similar
diseas
present
observ
human
contribut
tcell
mediat
immun
protect
ebov
challeng
mice
macaqu
recent
review
appear
vari
among
vaccin
candid
cellular
immun
respons
suggest
contribut
protect
mice
viruslik
particl
vaccin
vesicular
stomat
viru
base
vaccin
recent
protect
macaqu
mediat
adenoviru
vector
gp
attribut
tcell
deplet
prior
challeng
howev
protect
vaccin
macaqu
believ
induc
strong
cellular
immun
investig
tcell
respons
rvavector
gp
vaccin
pursu
comparison
candid
live
kill
vaccin
induc
primari
tcell
mediat
respons
measur
elispot
respons
rvgp
robust
mean
studi
memori
recal
respons
absenc
facil
use
vaccinia
viru
express
ebov
gp
surrog
challeng
viru
vaccin
candid
induc
high
level
recal
gpspecif
tcell
upon
challeng
two
dose
regim
inacrvgp
found
induc
tcell
par
rvgp
inactiv
vaccin
commonli
believ
weak
induc
tcell
immun
data
encourag
particularli
sinc
focus
inacrvgp
human
vaccin
develop
import
note
inacrvgp
inactiv
method
rabv
vaccin
current
use
human
requir
adjuv
result
indic
live
kill
vaccin
induc
cell
respons
indic
vaccin
strategi
induc
potent
humor
cell
mediat
immun
respons
next
sought
defin
humor
immun
respons
lead
candid
human
use
inacrvgp
assay
two
critic
paramet
abil
induc
multival
immun
immun
presenc
preexist
rabv
vaccin
vector
immun
epidemiolog
commerci
consider
effect
filoviru
vaccin
like
requir
induct
multival
immun
ebola
viru
zair
sudan
ebola
viru
marburg
viru
crossreact
amongst
filovirus
limit
welldefin
vaccin
multipl
immunogen
like
requir
achiev
dnaadenoviru
platform
vesicular
stomat
viru
platform
proofofprincipl
experi
demonstr
coadministr
inacrvgp
inactiv
rabv
vaccin
express
fragment
botulinum
neurotoxin
induc
humor
immun
rabv
g
botulinum
ebov
gp
compar
singl
administr
thu
inactiv
rabv
vaccin
platform
appear
wellsuit
induct
multival
immun
addit
rabv
vaccin
express
variou
filoviru
gp
pursu
final
vaccin
rabvimmun
mice
inacrvgp
demonstr
preexist
vector
immun
rabv
prevent
induct
gpspecif
antibodi
abil
effect
immun
mice
presenc
rabv
gspecif
antibodi
suggest
vaccin
strategi
may
effect
previous
rabvvaccin
human
boost
variou
rabv
vector
vaccin
may
success
find
import
mani
laboratori
worker
first
respond
soldier
might
receiv
ebov
vaccin
may
previous
immun
rabv
vaccin
although
preexist
immun
vsv
vector
vaccin
would
presum
low
issu
preexist
immun
gener
popul
adenoviru
paramyxoviru
vector
vaccin
rais
potenti
concern
taken
togeth
result
support
strong
potenti
use
rabv
vaccin
platform
mean
develop
inactiv
filoviru
vaccin
use
human
live
vaccin
use
nonhuman
primat
risk
ebov
infect
africa
three
critic
paramet
demonstr
induct
cellmedi
immun
abil
induc
multival
humor
respons
abil
immun
presenc
vector
immun
definit
immun
respons
vaccin
candid
shift
studi
macaqu
immunogen
efficaci
studi
nonhuman
primat
result
posit
outcom
believ
rabv
vaccin
platform
may
superior
strategi
filoviru
vaccin
base
consider
safeti
manufactur
cost
abil
also
confer
protect
rabv
still
major
public
health
problem
africa
live
kill
rabiesebola
vaccin
induc
ebov
gpspecif
tcell
coformul
inactiv
vaccin
induc
multival
humor
immun
humor
immun
induc
presenc
preexist
immun
rabv
mutat
glu
chang
amino
acid
rabv
g
shown
greatli
attenu
neurovirul
rabv
vaccin
vector
adult
mice
live
kill
rabv
vaccin
express
ebov
gp
induc
primari
b
memori
recal
tcell
immun
balbc
mice
immun
im
ffu
live
virus
inacrvgp
day
day
day
primari
cell
mediat
immun
analyz
day
postimmunizatio
splenocyt
suspens
gener
mous
individu
use
murin
elispot
r
system
use
ebov
gp
peptid
pool
unrel
flu
control
peptid
stimul
b
analysi
memori
cell
respons
six
mice
per
group
challeng
ip
pfu
vaccinia
viru
express
gp
four
week
postimmun
five
day
later
spleen
remov
elispot
perform
describ
primari
respons
result
mean
spot
per
million
cell
error
bar
standard
error
mean
p
p
unpair
ttest
show
signific
differ
sera
dilut
gp
group
either
singl
dose
group
higher
two
pvalu
shown
p
p
p
p
